BOULDER, Colo. ( TheStreet) -- Clovis Oncology (CLVS) is shutting down development of its experimental pancreatic cancer drug C0-101 following negative results from a late-stage study, the company said Monday.
Pancreatic cancer patients treated with CO-101 did not live any longer than patients treated with the chemotherapy drug gemcitabine. Median survival in each arm of the study was approximately six months.
"We are obviously disappointed with these results, which are unambiguous," said Clovis CEO Pat Mahaffy.
Clovis shares closed Friday at $21.49.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts